Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models | Intellectia.AI
Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models
Written by Emily J. Thompson, Senior Investment Analyst
Lunai Bioworks' Breakthrough Therapy: Lunai Bioworks has secured a Letter of Intent to license its Dendritic Cell Combination Therapy (DCCT), which has shown complete regression of pancreatic tumors in preclinical models, marking a significant advancement in cancer immunotherapy.
Clinical Development Plans: The company is preparing for a Phase I clinical trial targeting high-need solid tumors, including pancreatic cancer, and is advancing formal licensing negotiations and pre-IND activities for early 2026.
Expert Validation and Recognition: The therapy has received positive feedback from independent experts and researchers, with notable figures in the field highlighting its potential as a breakthrough in cancer treatment.
Scalable Off-the-Shelf Solution: Lunai's DCCT is designed to be an allogeneic immunotherapy that can be manufactured from healthy donor cells, significantly reducing treatment costs and manufacturing timelines compared to patient-specific therapies.
Lunai Bioworks, Inc., formerly Renovaro Inc., is focused on AI-powered biodefense, drug discovery and advanced diagnostics. The Company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
